The DOI matches its Crossref record, with a small difference in title or year.
Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance
Abstract
Mode of action of 5-fluorocytosine (5-FC) and mechanisms of resistance to the drug are discussed on the basis of experiments performed with Candida albicans ATCC 26790 and with 50 selected clinical isolates of C. albicans belonging to serological type A or B and representing various degrees and models of 5-FC resistance (sensitivity). Incorporation of 5-fluorouridylic acid into RNA appeared as a prerequisite to antifungal activity, although at a given incorporation rate, growth inhibition varied considerably from one strain to the other. The amino acid pool was unbalanced, and there was evidence for disturbance of protein synthesis. These dysfunctions of RNA probably account for growth inhibition and cell death, whereas up to the present, there was no proof of formation of 5-fluorodeoxyuridylic acid nor of subsequent inhibition of thymidylate synthetase. Incorporation of fluorinated pyrimidine into RNA was lower in normally sensitive type B strains than in normally sensitive ones of type A, whereas the frequency of 5-FC-resistant mutants was the same. The two serological types did not differ in the activity of cytosine permease nor in that of cytosine deaminase. Among 29 clinical isolates with 5-FC resistance (or impaired sensitivity) no instance of cytosine permease deficiency was found. Two isolates (belonging to the serological type A) were deficient in cytosine deaminase, whereas the majority was probably deficient in uridine monophosphate pyrophosphorylase or had a surplus of de novo synthesis of pyrimidines. Relative 5-FC resistance was more common than complete resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Sorted by citations
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,811
“albicans and Cryptococcus neoformans is attributable to mutational loss of one of the pyrimidine salvage enzymes (99, 108, 150).”
BackgroundVermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
“The occurrence of resistance with the use of 5-FC has been widely described and precludes use of 5-FC as a single agent.(5,11,17) Two basic mechanisms of resistance can be distinguished: (i) certain mutations can result in a deficiency in the enzymes necessary for cellular transport and uptake of 5-FC or for its metab…”
BackgroundAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2011) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 531
“Numerous enzymes of the pyrimidine salvage pathway are involved in 5FC mode of action and thus numerous molecular mechanisms could lead to resistance to this drug [16, 204].”
BackgroundInfluentialMullen, C. A., Kilstrup, M., & Blaese, R. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.33 · Cited by 495
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
“Use in other situations has been limited due to clinician concerns regarding drug toxicity and resistance development with monotherapy administration (35, 67, 73).”
Background
Metadata
- Authors
- Polak, A., & Scholer, H. J.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Polak, Annemarie
- Venue
- Chemotherapy
- Publisher
- S. Karger AG
- Published
- 2009-05-25
- Volume
- 21
- Issue
- 3-4
- Pages
- 113-130
- ISSN
- 0009-3157 (ISSN-L)
- 1421-9794
- OpenAlex
- W2072785474
- Cited by
- 250
- References
- 0
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 10 · 2023: 12 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 7 · 2018: 7 · 2017: 4 · 2016: 5 · 2015: 2 · 2014: 8 · 2013: 4 · 2012: 6
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- 5-fluorocytosine, Candida albicans, antifungal resistance, mechanism of action, cytosine deaminase, protein synthesis inhibition, clinical isolates
- MeSH terms
- Candida albicans, Cell Division, Cytidine Deaminase, Cytosine, Drug Resistance, Microbial, Flucytosine, RNA, Serotyping, Uracil Nucleotides, Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review